274 related articles for article (PubMed ID: 34226664)
1. Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation.
Lv SL; Zeng ZF; Gan WQ; Wang WQ; Li TG; Hou YF; Yan Z; Zhang RX; Yang M
Acta Pharmacol Sin; 2021 Dec; 42(12):2016-2032. PubMed ID: 34226664
[TBL] [Abstract][Full Text] [Related]
2. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Gan W; Ren J; Li T; Lv S; Li C; Liu Z; Yang M
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):1-10. PubMed ID: 28986310
[TBL] [Abstract][Full Text] [Related]
3. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin B-Mediated NLRP3 Inflammasome Formation and Activation in Angiotensin II -Induced Hypertensive Mice: Role of Macrophage Digestion Dysfunction.
Lian D; Lai J; Wu Y; Wang L; Chen Y; Zhang Y; Boini KM; Huang Y; Chen Y
Cell Physiol Biochem; 2018; 50(4):1585-1600. PubMed ID: 30359991
[TBL] [Abstract][Full Text] [Related]
5. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.
Wang WY; Zhang J; Wu WY; Li J; Ma YL; Chen WH; Yan H; Wang K; Xu WW; Shen JH; Wang YP
PLoS One; 2011; 6(8):e23425. PubMed ID: 21909350
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of NLRP3 Inflammasome Reverses Pressure Overload-Induced Pathological Cardiac Remodeling by Attenuating Hypertrophy, Fibrosis, and Inflammation.
Zhao M; Zhang J; Xu Y; Liu J; Ye J; Wang Z; Ye D; Feng Y; Xu S; Pan W; Wang M; Wan J
Int Immunopharmacol; 2021 Oct; 99():108046. PubMed ID: 34435581
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.
Hu MM; Zhang J; Wang WY; Wu WY; Ma YL; Chen WH; Wang YP
Acta Pharmacol Sin; 2011 Oct; 32(10):1253-8. PubMed ID: 21970837
[TBL] [Abstract][Full Text] [Related]
9. Nlrp3 Deficiency Alleviates Angiotensin II-Induced Cardiomyopathy by Inhibiting Mitochondrial Dysfunction.
Chen Y; Zeng M; Zhang Y; Guo H; Ding W; Sun T
Oxid Med Cell Longev; 2021; 2021():6679100. PubMed ID: 33628380
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL; Shi Y; Mohler ER; Hamamdzic D; Burgert ME; Li J; Postle A; Fenning RS; Bollinger JG; Hoffman BE; Pelchovitz DJ; Yang J; Mirabile RC; Webb CL; Zhang L; Zhang P; Gelb MH; Walker MC; Zalewski A; Macphee CH
Nat Med; 2008 Oct; 14(10):1059-66. PubMed ID: 18806801
[TBL] [Abstract][Full Text] [Related]
11. Effect of lipoprotein-associated phospholipase A2 inhibitor on insulin resistance in streptozotocin-induced diabetic pregnant rats.
Wang GH; Jin J; Sun LZ
Endocr J; 2018 Sep; 65(9):903-913. PubMed ID: 29925744
[TBL] [Abstract][Full Text] [Related]
12. Genetic invalidation of Lp-PLA
Gregson JM; Freitag DF; Surendran P; Stitziel NO; Chowdhury R; Burgess S; Kaptoge S; Gao P; Staley JR; Willeit P; Nielsen SF; Caslake M; Trompet S; Polfus LM; Kuulasmaa K; Kontto J; Perola M; Blankenberg S; Veronesi G; Gianfagna F; Männistö S; Kimura A; Lin H; Reilly DF; Gorski M; Mijatovic V; ; Munroe PB; Ehret GB; ; Thompson A; Uria-Nickelsen M; Malarstig A; Dehghan A; ; Vogt TF; Sasaoka T; Takeuchi F; Kato N; Yamada Y; Kee F; Müller-Nurasyid M; Ferrières J; Arveiler D; Amouyel P; Salomaa V; Boerwinkle E; Thompson SG; Ford I; Wouter Jukema J; Sattar N; Packard CJ; Shafi Majumder AA; Alam DS; Deloukas P; Schunkert H; Samani NJ; Kathiresan S; ; Nordestgaard BG; Saleheen D; Howson JM; Di Angelantonio E; Butterworth AS; Danesh J;
Eur J Prev Cardiol; 2017 Mar; 24(5):492-504. PubMed ID: 27940953
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Li Y; Li H; Liu S; Pan P; Su X; Tan H; Wu D; Zhang L; Song C; Dai M; Li Q; Mao Z; Long Y; Hu Y; Hu C
Mol Immunol; 2018 Jul; 99():134-144. PubMed ID: 29783158
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2.
Fenning RS; Burgert ME; Hamamdzic D; Peyster EG; Mohler ER; Kangovi S; Jucker BM; Lenhard SC; Macphee CH; Wilensky RL
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25672369
[TBL] [Abstract][Full Text] [Related]
15. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
Daida H; Iwase T; Yagi S; Ando H; Nakajima H
Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
[TBL] [Abstract][Full Text] [Related]
16. SIRT3 (Sirtuin-3) Prevents Ang II (Angiotensin II)-Induced Macrophage Metabolic Switch Improving Perivascular Adipose Tissue Function.
Wei (魏彤) T; Gao (高晶) J; Huang (黄程淋) C; Song (宋蓓) B; Sun (孙孟炜) M; Shen (沈伟利) W
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):714-730. PubMed ID: 33327751
[TBL] [Abstract][Full Text] [Related]
17. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin (1-7) inhibits arecoline-induced migration and collagen synthesis in human oral myofibroblasts via inhibiting NLRP3 inflammasome activation.
You Y; Huang Y; Wang D; Li Y; Wang G; Jin S; Zhu X; Wu B; Du X; Li X
J Cell Physiol; 2019 Apr; 234(4):4668-4680. PubMed ID: 30246378
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D
PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643
[TBL] [Abstract][Full Text] [Related]
20. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
